Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for the securities of the Company.

China Castson 81 Finance Company Limited
中國鑄晨81金融有限公司

(Continued into Bermuda with limited liability)

(Stock Code: 810)

(1) POLL RESULTS OF THE SPECIAL GENERAL MEETING HELD ON 2 MARCH 2026; AND (2) GRANT OF WHITEWASH WAIVER

References are made to the circular (the "**Circular**") and the notice (the "**SGM Notice**") of the special general meeting (the "**SGM**") of China Castson 81 Finance Company Limited (the "**Company**") both dated 27 January 2026 in relation to, among other things, the Rights Issue. Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Circular.

As at the date of the SGM, the total number of issued Shares of the Company was 203,643,187 and the Company did not hold any treasury shares or repurchased Shares pending for cancellation. In accordance with the Takeovers Code and the Listing Rules, Dr. Lam, Goodchamp and parties acting in concert with either of them and their associates were required to abstain from voting on the relevant resolution(s) in respect of the Rights Issue, the Underwriting Agreement and the transactions contemplated thereunder as well as the Whitewash Waiver at the SGM. As a result, a total of 35,305,770 Shares indirectly held by Dr. Lam were required to abstain, and had been abstained, from voting on the relevant resolutions at the SGM. Accordingly, holders of 168,337,417 Shares were entitled to attend and vote for or against on resolutions at the SGM.

Save as disclosed above, no other Shareholder is required to abstain from voting on the resolutions to approve the Rights Issue, the Underwriting Agreement and the transactions contemplated thereunder as well as the Whitewash Waiver at the SGM under the Listing Rules and the Takeovers Code. No Shareholder has stated his/her/its intention in the Circular to vote against or abstain from voting on any of the resolutions at the SGM. There were no Shares entitling the holders to attend and abstain from voting in favour of the resolutions at the SGM as set out in Rule 13.40 of the Listing Rules.

The SGM was chaired by Mr. Tam Yuk Sang, Sammy, an independent non-executive Director. All the Directors attended the SGM in person or by electronic means.

POLL RESULTS OF THE SGM

The poll at the SGM was scrutinised by Tricor Investor Services Limited, the Company's branch share registrar in Hong Kong. All resolutions were approved by the Independent Shareholders and the poll results were as follows:

ORDINARY RESOLUTION *(Note)*	**Number of Votes (%)**	
	FOR	**AGAINST**
To approve the Rights Issue, the Underwriting Agreement and the transactions contemplated thereunder	27,690,042 100.00%	0 0.00%
SPECIAL RESOLUTION *(Note)*	**Number of Votes (%)**	
	FOR	**AGAINST**
To approve the Whitewash Waiver and the transactions contemplated thereunder	27,690,042 100.00%	0 0.00%

Note: The full text of the resolutions are set out in the SGM Notice.

As more than 50% of the votes were cast in favour of the above ordinary resolution, such resolution was duly passed as ordinary resolution of the Company by the Independent Shareholders at the SGM by way of poll. As more than 75% of the votes were cast in favour of the above special resolution, such resolution was duly passed as special resolution of the Company by the Independent Shareholders at the SGM by way of poll.

EFFECT ON THE SHAREHOLDING STRUCTURE OF THE COMPANY ARISING FROM THE RIGHTS ISSUE

Assuming there is no further issue or repurchase of Shares from the date of this announcement up to and including the date of completion of the Rights Issue, the table below sets out the shareholding structure of the Company (i) as at the date of this announcement; (ii) immediately upon completion of the Rights Issue assuming full acceptance by all Shareholders; (iii) immediately upon completion of the Rights Issue, assuming none of the Qualifying Shareholders have taken up any entitled Rights Shares (other than those subscriptions pursuant to the Irrevocable Undertaking) and all the Unsubscribed Rights Shares and the ES Unsold Rights Shares (if any) have been placed by the Placing Agent; and (iv) immediately upon completion of the Rights Issue, assuming none of the Qualifying Shareholders have taken up any entitled Rights Shares (other than those subscriptions pursuant to the Irrevocable Undertaking) and none of the Unsubscribed Rights Shares and the ES Unsold Rights Shares (if any) have been placed by the Placing Agent, all the Unsubscribed Rights Shares and the ES Unsold Rights Shares (if any) were subscribed for through the Underwriter up to the Underwritten Shares, for illustrative purpose:

	(i) As at the date of this announcement		**(ii) Immediately upon completion of the Rights Issue assuming full acceptance by all Qualifying Shareholders**		**(iii) Immediately upon completion of the Rights Issue, assuming none of the Qualifying Shareholders have taken up any entitled Rights Shares (other than those subscriptions pursuant to the Irrevocable Undertaking) and all the Unsubscribed Rights Shares and the ES Unsold Rights Shares (if any) have been placed by the Placing Agent**		**(iv) immediately upon completion of the Rights Issue, assuming none of the Qualifying Shareholders have taken up any entitled Rights Shares (other than those subscriptions pursuant to the Irrevocable Undertaking) and none of the Unsubscribed Rights Shares and the ES Unsold Rights Shares (if any) have been placed by the Placing Agent, all the Unsubscribed Rights Shares and the ES Unsold Rights Shares (if any) were subscribed for through the Underwriter up to the Underwritten Shares**	
	No. of Shares	*%*	*No. of Shares*	*%*	*No. of Shares*	*%*	*No. of Shares*	*%*
Shareholders								
Goodchamp, Dr. Lam and parties acting in concert with either of them *(note 1)*	35,305,770	17.34	123,570,195	17.34	123,570,195	17.34	504,570,195 *(note 2)*	74.98
The Independent Placees	–	–	–	–	420,843,542	59.04	–	–
Other public Shareholders	168,337,417	82.66	589,180,959	82.66	168,337,417	23.62	168,337,417	25.02
	203,643,187	100.00	712,751,154	100.00	712,751,154	100.00	672,907,612	100.00

Notes:

1. The issued share capital of Goodchamp is wholly owned by Dr. Lam, a chairman of the Board and a non-executive Director.

2. As at the date of this announcement, Goodchamp has provided the Irrevocable Undertaking to the Company, irrevocable undertaking to subscribe for the Rights Shares to be provisionally allotted to it (i.e., 88,264,425 Rights Shares); and Goodchamp, as the Underwriter, has conditionally agreed to subscribe for up to 381,000,000 Rights Shares (i.e., the Underwritten Shares). Immediately upon completion of the Rights Issue, assuming none of the Qualifying Shareholders have taken up any of their entitlement under the Rights Shares (other than those subscriptions pursuant to the Irrevocable Undertaking) and none of the Unsubscribed Rights Shares and the ES Unsold Rights Shares (if any) have been placed by the Placing Agent, all the Unsubscribed Rights Shares and the ES Unsold Rights Shares (if any) were subscribed for through the Underwriter up to the Underwritten Shares, Goodchamp will hold 504,570,195 Shares, representing approximately 74.98% of the total issued Shares of the Company as enlarged by the allotment and issue of the Rights Share. The Executive has granted the Whitewash Waiver on 25 February 2026 (details of which are set out below in this announcement).

3. Save for Dr. Lam (through Goodchamp), no Director holds any relevant securities of the Company as at the date of this announcement.

4. The percentage of shareholding in the above table is for illustrative purpose only. The Company will take all appropriate steps to ensure that sufficient public float be maintained in compliance with the Public Float Requirement.

5. Certain percentage figures included in the above table are subject to rounding adjustments. Accordingly, figures shown as totals may not be an arithmetic aggregation of the figures preceding them.

GRANT OF WHITEWASH WAIVER

The Executive has granted the Whitewash Waiver on 25 February 2026, subject to:

(i) (a) the Whitewash Waiver; and (b) the Rights Issue, the Underwriting Agreement, and the transactions contemplated thereunder being separately approved by at least (a) 75% and (b) more than 50% respectively of the independent vote (as defined in Note 1 on dispensations from Rule 26 of the Takeovers Code) that are cast either in person or by proxy at the SGM, to be taken on a poll; and

(ii) unless the Executive gives prior consent, no acquisition or disposal of voting rights being made by the Underwriter, Dr. Lam and parties acting in concert with any of them between the Announcement and the completion of the Rights Issue.

COMMENCEMENT OF DEALINGS IN THE SHARES ON AN EX-RIGHT BASIS AND DESPATCH OF THE PROSPECTUS DOCUMENTS

The Rights Issue is expected to proceed in accordance with the expected timetable as set out in the Circular. Pursuant to the expected timetable, it is expected that the last day of dealing in the Shares on a cum-rights basis will be Tuesday, 3 March 2026, and the first day of dealing in the Shares on an ex-rights basis will be Wednesday, 4 March 2026. The Prospectus Documents are expected to be made available to the Qualifying Shareholders (in the case of the Excluded Shareholders, the Prospectus for information only) on Friday, 13 March 2026. Details of the Rights Issue including, among others, the effects of the Rights Issue on the shareholding structure of the Company are set out in the Circular.

WARNING OF THE RISKS OF DEALING IN SHARES AND RIGHTS SHARES

Shareholders and potential investors of the Company should note that the Rights Issue is conditional upon, among others, the Underwriting Agreement having become unconditional and the Underwriter not having terminated the Underwriting Agreement in accordance with the terms thereof (a summary of which is set out in the sections headed "Conditions of the Rights Issue" and "Termination of the Underwriting Agreement" in the Circular). Accordingly, the Rights Issue may or may not proceed.

Any Shareholder or other person dealing in the Shares and/or the nil-paid Rights Shares up to the date on which all the conditions to which the Rights Issue are fulfilled (and the date on which the Underwriters' right of termination of the Underwriting Agreement ceases) will accordingly bear the risk that the Rights Issue may not become unconditional or may not proceed.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Shares and/or the nil-paid Rights Shares. Any party (including Shareholders and potential investors of the Company) who is in any doubt about his/her/its position or any action to be taken is recommended to consult his/her/its own professional adviser(s).

By order of the Board
China Castson 81 Finance Company Limited
Lee Kwok Leung
Director

Hong Kong, 2 March 2026

As at the date of this announcement, the executive Director is Mr. Lee Kwok Leung; the non-executive Director is Dr. Lam Man Chan; and the independent non-executive Directors are Dr. Ng Chi Yeung, Simon, Mr. Tam Yuk Sang, Sammy, and Ms. Law So Fun.

The Directors jointly and severally accept full responsibility for the accuracy of information contained in this announcement and confirm, having made all reasonable inquiries, that to the best of their knowledge, opinions expressed in this announcement have been arrived at after due and careful consideration and there are no other facts not contained in this announcement, the omission of which would make any statement in this announcement misleading.